Anomalie congenite dei reni e delle vie urinarie (CAKUT)

Autor: Francesca Liut, Claudia Izzi, Nadia Dallera, Francesco Scolari

Publikováno v: Giornale di Clinica Nefrologia e Dialisi, Vol 28, Iss 2 (2016)

Abstract non disponibile

Externí odkaz: https://doaj.org/article/919123878ee5481aa96cff8016293923

P0057ADPKD: COMPLEX GENOTYPES MAY EXPLAIN SEVERE PHENOTYPE AND INTRAFAMILIAL PHENOTYPIC VARIABILITY

Autor: Elisa Delbarba, Gianfranco Savoldi, Claudia Izzi, Nadia Dallera, Chiara Dordoni, Francesco Scolari, Cinzia Mazza, Laura Econimo

Publikováno v: Nephrology Dialysis Transplantation. 35

Background and Aims Discordant affected relative-pairs are seen in ∼10% of families with Autosomal Dominant Polycystic Kidney Disease (ADPKD); Method Among our single-center ADPKD cohort (186 index patients), we selected pedigrees (P) in which mark

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::01788fb18aaf8868ccfda33a09361fcc
https://doi.org/10.1093/ndt/gfaa142.p0057

Cholesterol crystal embolism (atheroembolism)

Autor: Francesco Scolari, Nadia Dallera, Laura Sottini, Guido Jeannin, Chiara Venturelli

Publikováno v: Heart International, Vol 2, Iss 3-4 (2006)

Cholesterol crystal embolism, known as atheroembolic disease, is caused by showers of cholesterol crystals from an atherosclerotic plaque that occludes small arteries. Embolization can occur spontaneously or as an iatrogenic complication from an inva

Externí odkaz: https://doaj.org/article/f7b9f6c07f22443e8589f9216fee67fa

Tubulointerstitial nephritis is a dominant feature of hereditary apolipoprotein A-I amyloidosis

Autor: Pietro Ravani, Tiziano Scalvini, Gina Gregorini, Alessandro Negrinelli, Giampaolo Merlini, Andrea Del Barba, L. Biasi, Claudia Izzi, Francesco Scolari, Nadia Dallera, Laura Obici, Matilde Nardi, Regina Tardanico

Publikováno v: Kidney International. 87:1223-1229

Apolipoprotein A-I is the main protein of high-density lipoprotein particles, and is encoded by the APOA1 gene. Several APOA1 mutations have been found, either affecting the lecithin:cholesterol acyltransferase activity, determining familial HDL defi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfacf42afca009cd08266f9b233f5936
https://doi.org/10.1038/ki.2014.389

Rituximab versus steroids and cyclophosphamide for the treatment of primary membranous nephropathy: protocol of a pilot randomised controlled trial

Autor: Piergiorgio Messa, Antonello Pani, Francesco Scolari, Loreto Gesualdo, Riccardo Magistroni, Marisa Santostefano, Giuliano Boscutti, Domenico Santoro, Marco Quaglia, Nadia Dallera, Pietro Ravani, Sandro Feriozzi, Laila Yasmin Mani, Claudio Ponticelli

Publikováno v: BMJ Open
Scolari, Francesco; Dallera, Nadia; Gesualdo, Loreto; Santoro, Domenico; Pani, Antonello; Santostefano, Marisa; Feriozzi, Sandro; Mani, Laila-Yasmin; Boscutti, Giuliano; Messa, Piergiorgio; Magistroni, Riccardo; Quaglia, Marco; Ponticelli, Claudio; Ravani, Pietro (2019). Rituximab versus steroids and cyclophosphamide for the treatment of primary membranous nephropathy: protocol of a pilot randomised controlled trial. BMJ open, 9(12), e029232. BMJ Publishing Group 10.1136/bmjopen-2019-029232

IntroductionPrimary membranous nephropathy (MN) is a common cause of nephrotic syndrome in adults. The disease may have different long-term outcomes. After 10 years of follow-up, 35%–50% of the untreated patients with persistent nephrotic syndrome

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d738093f636bf400f9cb2a294be7d2c
https://doi.org/10.1136/bmjopen-2019-029232